71 related articles for article (PubMed ID: 18183549)
1. Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study.
Vila Nova B; Cunha E; Sepúlveda N; Oliveira M; São Braz B; Tavares L; Almeida V; Gil S
BMC Vet Res; 2018 Nov; 14(1):348. PubMed ID: 30445957
[TBL] [Abstract][Full Text] [Related]
2. Clinical assessment of a point-of-care assay to determine protective vaccinal antibody titers to canine viral diseases.
Ad Y; Halperin IM; Olstad EC; Gershwin LJ; Sullivan L; Reagan KL
Vet J; 2023; 298-299():106017. PubMed ID: 37524148
[TBL] [Abstract][Full Text] [Related]
3. Early administration of canine parvovirus monoclonal antibody prevented mortality after experimental challenge.
Larson L; Miller L; Margiasso M; Piontkowski M; Tremblay D; Dykstra S; Miller J; Slagter BJ; Champ D; Keil D; Patel M; Wasmoen T
J Am Vet Med Assoc; 2024 Apr; 262(4):506-512. PubMed ID: 38295522
[TBL] [Abstract][Full Text] [Related]
4. Isolation and genetic characterization of canine adenovirus type 2 from a domestic dog showing neurological symptoms.
Chander V; Sharma GK; Bhatt M; Nandi S; Mahajan S; Singh M; Mahendran K; Karikalan M; Pawde AM; Gupta V; Singh KP; Rajak KK; Gupta VK; Singh RK
Braz J Microbiol; 2021 Dec; 52(4):2521-2528. PubMed ID: 34128211
[TBL] [Abstract][Full Text] [Related]
5. Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
Blake JM; Thompson J; HogenEsch H; Ekenstedt KJ
Vaccine; 2024 Apr; 42(12):3099-3106. PubMed ID: 38604911
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for death from canine parvoviral-related disease in Australia.
Ling M; Norris JM; Kelman M; Ward MP
Vet Microbiol; 2012 Aug; 158(3-4):280-90. PubMed ID: 22424864
[TBL] [Abstract][Full Text] [Related]
7. Development of a Novel Canine Parvovirus Vaccine Capable of Stimulating Protective Immunity in Four-Week-Old Puppies in the Face of High Levels of Maternal Antibodies.
Pearce J; Spibey N; Sutton D; Tarpey I
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766175
[TBL] [Abstract][Full Text] [Related]
8. Growth characteristics of canine pathogenic viruses in MDCK cells cultured in RPMI 1640 medium without animal protein.
Mochizuki M
Vaccine; 2006 Mar; 24(11):1744-8. PubMed ID: 16271422
[TBL] [Abstract][Full Text] [Related]
9. Assessing the immunogenicity of an inactivated monovalent vaccine in the endangered African wild dog (
Anderson N; Smith I
Vaccine X; 2019 Apr; 1():100006. PubMed ID: 31384728
[TBL] [Abstract][Full Text] [Related]
10. Erratum for "Vaccine-associated leptospira antibodies in client-owned dogs".
J Vet Intern Med; 2022 Sep; ():. PubMed ID: 36173182
[No Abstract] [Full Text] [Related]
11. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
De Cramer KG; Stylianides E; van Vuuren M
Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542
[TBL] [Abstract][Full Text] [Related]
12. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.
Aida V; Pliasas VC; Neasham PJ; North JF; McWhorter KL; Glover SR; Kyriakis CS
Front Vet Sci; 2021; 8():654289. PubMed ID: 33937377
[TBL] [Abstract][Full Text] [Related]
13. Novel Genotype Definition and the First Epidemiological Investigation of Canine Adenovirus Type 2 in Dogs in Central China.
Ji J; Li W; Hu W; Xu X; Kan Y; Yao L; Bi Y; Xie Q
Front Vet Sci; 2020; 7():534. PubMed ID: 32974402
[TBL] [Abstract][Full Text] [Related]
14. Canine vaccination in Germany: A survey of owner attitudes and compliance.
Eschle S; Hartmann K; Rieger A; Fischer S; Klima A; Bergmann M
PLoS One; 2020; 15(8):e0238371. PubMed ID: 32853287
[TBL] [Abstract][Full Text] [Related]
15. Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group.
Day MJ; Crawford C; Marcondes M; Squires RA
J Small Anim Pract; 2020 Jun; 61(6):E1-E35. PubMed ID: 32227347
[TBL] [Abstract][Full Text] [Related]
16. A novel assay for detecting canine parvovirus using a quartz crystal microbalance biosensor.
Kim YK; Lim SI; Choi S; Cho IS; Park EH; An DJ
J Virol Methods; 2015 Jul; 219():23-27. PubMed ID: 25813597
[TBL] [Abstract][Full Text] [Related]
17. The challenges in developing effective canine infectious respiratory disease vaccines.
Mitchell JA; Brownlie J
J Pharm Pharmacol; 2015 Mar; 67(3):372-81. PubMed ID: 25736813
[TBL] [Abstract][Full Text] [Related]
18. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine.
Larson LJ; Schultz RD
Vet Ther; 2007; 8(4):305-10. PubMed ID: 18183549
[TBL] [Abstract][Full Text] [Related]
19. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
